Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of ASND is 245 and suggests 15% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell